Irina Bancos, M.D., M.S.

The purpose of this study is to seek understanding of how patients with adrenal insufficiency perceive their health and quality of life, and to identify predictors of unfavorable measure of health/quality of life.

The purpose of this study is to determine prevalence and incidence of osteopenia, osteoporosis, and fractures in patients with adenomas based on hormonal sub-type, and to determine the effect of abnormal steroid metabolome on bone density, bone metabolism, and fractures.

The purpose of this study is to determine the diagnostic accuracy of salivary cortisol and cortisone in diagnosing Mild autonomous cortisol secretion.

The purpose of this study is to determine the association of environmental, geographic factors, as well as presence of comorbidities associated with hypoxia with development of pheochromocytomas and paragangliomas (PPGL), location of PPGL, and number of PPGL.

The purpose of this study is to evaluate the safety and tolerability of metyrapone therapy in patients with mild autonomous cortisol secretion (MACS). Also, to determine the impact of metyrapone therapy on steroid profiling and circadian cortisol secretion and to determine the efficacy of metyrapone therapy on metabolic parameters, cognition, frailty, and senescence as initial proof-of-concept for a larger randomized clinical trial.

The purpose of this study is to establish incidence and prevalence of Impulse Control Disorders (ICDs) in patients with prolactinomas treated with dopamine agonists (DA), to determine the predictors of ICD development, and to establish a predictor scoring system that could be subsequently validated and applied prior to initiation of DA.

The purpose of this research is to follow people with adrenal disorders in order to make conclusions about the natural history of a particular adrenal disease as well as effect of various therapies and interventions decided on by you and your medical team. In addition, we will collect biomaterial from you at times you are being evaluated which will be used to discover novel biomarkers which can potentially improve the accuracy of current diagnostic tests and affect the management of patients with adrenal disorders. We will also include a control group (without known adrenal disease) to compare to the volunteers with adrenal disorders.

The primary purpose of this study is to determine pre-surgical and post-surgical predictors of the duration and severity of glucocorticoid withdrawal in patients undergoing a curative surgery for cortisol excess.

The purpose of this study is to evaluate the change from  baseline  in systolic blood pressure (SBP) by automated office blood  pressure monitoring  (AOBPM), with each dose  of CIN-107 compared to placebo, after 4 weeks of treatment in patients with PA.

The purpose of this study is to evaluate the long-term safety and effectiveness of Lonapegsomatropin administered once-weekly. 

The primary purpose of this study is to further document the long-term safety and tolerability profile of osilodrostat in routine clinical practice over a 3-year follow-up period when administered as monotherapy or in combination with other therapies in patients with endogenous Cushing’s Syndrome (CS).

The purpose of this study is to evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).

The purpose of this trial is to assess the long-term safety of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Anticipate approximately 70 patients enrolled from start in this trial and approximately 70 patients to roll-over from trial NCT04076462.

The purpose of this study is to assess the effectiveness and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.

The purpose of this study is to compare the effectiveness, safety, and tolerability of Chronocort (study drug) with standard of care medication, Immediate-Release Hydrocortisone (IRHC-Cortef) on subjects and their condition (CAH) to find out which is better.

The purpose of this study is to evaluate the potential of Tildacerfont to reduce glucocorticoid (GC) burden in adult subjects with classic Classic Congenital Adrenal Hyperplasia (CAH) who have lower limit of detection (LLD) ≤ A4 ≤ 1.5 x upper limit of normal (ULN) and are on supraphysiologic doses of GC therapy.

The purpose of this study is to evaluate the effectiveness of NBI-74788 (100 mg twice daily [bid]), compared with placebo, in reducing daily glucocorticoid dosage while maintaining adrenal androgen control, in reducing adrenal steroid levels following an initial 4-week treatment period, on clinical endpoints associated with supraphysiologic (greater than normal) glucocorticoid dosing, to evaluate plasma concentrations of NBI-74788 and metabolites, and to assess the safety and tolerability of NBI-74788.

The purpose of this study is to evaluate the effect of Tildacerfont in reducing androstenedione (hormone, A4) in subjects with Classic Adrenal Hyperplasia (CAH) over approximately 86 weeks.

The purpose of this study is to determine the effect of bilateral salpingo-oophorectomy (BSO) on adrenal aging as measured by the 24h urine steroid metabolome and as compared to the age-matched postmenopausal women.  

The purpose of this study is to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.

The purpose of this study is to characterize adrenal steroid synthesis and metabolism in patients with nonfunctioning adrenal tumors (NF), adrenal tumors with subclinical Cushing Syndrome (SCS) and Cushing Syndrome (CS). The study also aims to characterize altered metabolites and disruptive metabolic pathways, and to connect adrenalectomy-induced changes in β-cell function and insulin sensitivity with the preoperative metabolic profile in patients who have NF, SCS and CS adrenal tumors.

The purpose of this study is to establish a reference range for free cortisol following dexamethasone administration in 100 volunteers without suspicion of cortisol excess.

The purpose of this study is to determine the abnormalities in urine steroid profiling and association to the daily opioid dose in patients treated with opioids as compared to the existent cohort of healthy controls, and to identify the steroid signature associated with low quality of life, including physical and mental health.

The purpose of this study is to evaluate the efficacy of once-weekly lonapegsomatropin compared to placebo at 38 weeks in adults with growth hormone deficiency (GHD).

The purpose of this study is to assess the effectiveness of Relacorilant for the treatment of hypercortisolism in patients with cortisol-secreting adrenal adenomas or hyperplasia, based on glycemic and blood pressure (BP) control at Week 22 compared with placebo. and to assess the safety of relacorilant for the treatment of hypercortisolism.

Cushing's syndrome is a relatively rare disorder caused by prolonged exposure to high levels of the glucocorticoid hormone cortisol. Cushing's syndrome may result from elevated endogenous or exogenous sources of cortisol. Endogenous Cushing's syndrome resulting from cortisol overproduction by the adrenal glands is the subject of this protocol. Patients with exogenous Cushing's syndrome, which develops as a side effect of chronic administration of high doses of glucocorticoids, are not eligible for enrollment in this study. The purpose of this study is to evaluate the safety and efficacy of CORT125134 for treatment of endogenous Cushing's syndrome. The multicenter study will be conducted in the United States and in Europe.

The purpose of this study is to establish incidence and prevalence of Impulse Control Disorders (ICDs) in patients with prolactinomas treated with dopamine agonists (DA), to determine the predictors of ICD development, and to establish a predictor scoring system that could be subsequently validated and applied prior to initiation of DA.

This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.

The purpose of this study is to find out about the safety and effectiveness of an experimental drug called SPI-62 for the treatment of Cushing’s syndrome. Experimental means that the drug is not approved by health authorities including the United States Food and Drug Administration (FDA) for the treatment of Cushing’s syndrome.

The study's primary goal is to learn more about the possible impact of SPI-62 on the type of Cushing’s syndrome subject's have. The study's secondary goal is to assess SPI-62's safety and side effects, if any. Additionally, the study will look at the possible effect of SPI-62 on blood sugar (glucose) and fat (lipid) levels, body weight, liver function, eye function, anxiety, mood, brain function, bone strength, and muscle strength will also be checked in this study.

Cushing's syndrome is caused by an excess of cortisol, a hormone produced by the adrenal glands. SPI-62 has the potential to reduce symptoms associated with Cushing’s syndrome by possibly reducing the amount of cortisol inside cells in different parts of the body, such as the liver, fat, and bones.

The purpose of this study is to evaluate the effectiveness, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor.

The purpose of this study is to determine the effect of estrogen-based contraceptive therapy on baseline and peak total and free cortisol levels in healthy women undergoing the Cosyntropin stimulation test.